Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients.

Shafi T, Sozio SM, Plantinga LC, Jaar BG, Kim ET, Parekh RS, Steffes MW, Powe NR, Coresh J, Selvin E.

Diabetes Care. 2013 Jun;36(6):1522-33. doi: 10.2337/dc12-1896. Epub 2012 Dec 18.

2.

Fructosamine and Glycated Albumin and the Risk of Cardiovascular Outcomes and Death.

Selvin E, Rawlings AM, Lutsey PL, Maruthur N, Pankow JS, Steffes M, Coresh J.

Circulation. 2015 Jul 28;132(4):269-77. doi: 10.1161/CIRCULATIONAHA.115.015415. Epub 2015 May 28.

3.

Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study.

Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M, Coresh J.

Lancet Diabetes Endocrinol. 2014 Apr;2(4):279-88. doi: 10.1016/S2213-8587(13)70199-2. Epub 2014 Jan 15.

4.

Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients.

Mittman N, Desiraju B, Fazil I, Kapupara H, Chattopadhyay J, Jani CM, Avram MM.

Kidney Int Suppl. 2010 Aug;(117):S41-5. doi: 10.1038/ki.2010.193.

PMID:
20671744
5.

Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma.

Paroni R, Ceriotti F, Galanello R, Battista Leoni G, Panico A, Scurati E, Paleari R, Chemello L, Quaino V, Scaldaferri L, Lapolla A, Mosca A.

Clin Biochem. 2007 Dec;40(18):1398-405. Epub 2007 Aug 10.

6.

Nontraditional markers of glycemia: associations with microvascular conditions.

Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, Steffes MW.

Diabetes Care. 2011 Apr;34(4):960-7. doi: 10.2337/dc10-1945. Epub 2011 Feb 18.

7.

Racial Differences in and Prognostic Value of Biomarkers of Hyperglycemia.

Parrinello CM, Sharrett AR, Maruthur NM, Bergenstal RM, Grams ME, Coresh J, Selvin E.

Diabetes Care. 2016 Apr;39(4):589-95. doi: 10.2337/dc15-1360. Epub 2015 Dec 17.

8.

Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients.

Freedman BI, Andries L, Shihabi ZK, Rocco MV, Byers JR, Cardona CY, Pickard MA, Henderson DL, Sadler MV, Courchene LM, Jordan JR, Balderston SS, Graham AD, Mauck VL, Russell GB, Bleyer AJ.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1635-43. doi: 10.2215/CJN.11491210. Epub 2011 May 19.

9.

Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.

Konya J, Ng JM, Cox H, Cooke M, Lewis N, Bhandari S, Atkin SL, Kilpatrick ES.

Diabet Med. 2013 Oct;30(10):1250-4. doi: 10.1111/dme.12249. Epub 2013 Jul 9.

PMID:
23758176
10.

Alternative markers of hyperglycemia and risk of diabetes.

Juraschek SP, Steffes MW, Miller ER 3rd, Selvin E.

Diabetes Care. 2012 Nov;35(11):2265-70. doi: 10.2337/dc12-0787. Epub 2012 Aug 8.

11.

Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring.

Vos FE, Schollum JB, Coulter CV, Manning PJ, Duffull SB, Walker RJ.

Nephrology (Carlton). 2012 Feb;17(2):182-8. doi: 10.1111/j.1440-1797.2011.01517.x.

PMID:
21883672
12.

Glycated albumin predicts the risk of mortality in type 2 diabetic patients on hemodialysis: evaluation of a target level for improving survival.

Isshiki K, Nishio T, Isono M, Makiishi T, Shikano T, Tomita K, Nishio T, Kanasaki M, Maegawa H, Uzu T; Lake Biwa Clinical Dialysis Meeting.

Ther Apher Dial. 2014 Oct;18(5):434-42. doi: 10.1111/1744-9987.12123. Epub 2013 Nov 20.

PMID:
24251784
13.

Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management.

Parrinello CM, Selvin E.

Curr Diab Rep. 2014;14(11):548. doi: 10.1007/s11892-014-0548-3. Review.

14.

The Effect of Glycated Hemoglobin and Albumin-Corrected Glycated Serum Protein on Mortality in Diabetic Patients Receiving Continuous Peritoneal Dialysis.

Peng F, Xia X, He F, Li Z, Huang F, Yu X.

Perit Dial Int. 2015 Sep-Oct;35(5):566-75. doi: 10.3747/pdi.2014.00011. Epub 2014 Nov 13.

15.

Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose.

Juraschek SP, Steffes MW, Selvin E.

Clin Chem. 2012 Dec;58(12):1648-55. doi: 10.1373/clinchem.2012.188367. Epub 2012 Sep 27.

16.

Serum glycated albumin and fructosamine in renal dialysis patients.

Lamb E, Venton TR, Cattell WR, Dawnay A.

Nephron. 1993;64(1):82-8.

PMID:
8502341
17.

Serum fructosamine and risk of cardiovascular and all-cause mortality: a 24-year prospective population-based study.

Zaccardi F, Kurl S, Pitocco D, Ronkainen K, Laukkanen JA.

Nutr Metab Cardiovasc Dis. 2015 Feb;25(2):236-41. doi: 10.1016/j.numecd.2014.09.007. Epub 2014 Oct 5.

PMID:
25445881
18.

Glycated albumin, not hemoglobin A1c, predicts cardiovascular hospitalization and length of stay in diabetic patients on dialysis.

Murea M, Moran T, Russell GB, Shihabi ZK, Byers JR, Andries L, Bleyer AJ, Freedman BI.

Am J Nephrol. 2012;36(5):488-96. doi: 10.1159/000343920. Epub 2012 Nov 7.

PMID:
23147746
19.

HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions.

Ribeiro RT, Macedo MP, Raposo JF.

Curr Diabetes Rev. 2016;12(1):14-9. Review.

PMID:
26126638
20.

Glycated hemoglobin of fractionated erythrocytes, glycated albumin, and plasma fructosamine during pregnancy.

Kurishita M, Nakashima K, Kozu H.

Am J Obstet Gynecol. 1992 Nov;167(5):1372-8.

PMID:
1442993

Supplemental Content

Support Center